Pfizer (PFE) Enterprise Value (2009 - 2026)

Over the twelve months ended Sep 27, 2026, Pfizer's Enterprise Value came in at $111.13 billion, up 60.2% year-over-year; for FY2025, it came in at $128.29 billion, down 1.4% from FY2024.

• Enterprise Value has declined for four consecutive years, with a five-year compound annual growth rate of -7.9% (FY2020 to FY2025).
• By year, Enterprise Value came in at $130.17 billion in FY2024 (-13.3%), $150.15 billion in FY2023 (-43.4%), $265.45 billion in FY2022 (-11.9%) and $301.25 billion in FY2021 (+55.8%).
• The Q3 2026 figure ranks as the highest quarterly Enterprise Value since Q3 2024.
• Year over year, Enterprise Value has now increased in each of the last three quarters, with an average decline of 3.8% over the last eight quarters.
• The high point for year-over-year Enterprise Value in five years was Q4 2021 (growth of 55.8%); the low point was Q4 2023 (a decline of 43.4%).
• Per Business Quant data, the three quarters before Q3 2026 came in at $127.05 billion (Q2 2026), $141.34 billion (Q1 2026) and $128.29 billion (Q4 2025).